Aragen Bioscience Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aragen bioscience inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aragen Bioscience Inc Today - Breaking & Trending Today

Aragen Life Sciences: Goldman Sachs buys stake in contract research firm Aragen Life Sciences

Synopsis
Aragen is a leading provider of outsourced discovery, development, and manufacturing services across both large and small molecule platforms. The company serves a worldwide customer base which spans to the United States, Europe, and Japan.
Wall Street behemoth Goldman Sachs has taken a significant minority stake in Aragen Life Sciences, formerly known as GVK Biosciences, a leading contract research organization (CRO), the company announced today.
Goldman Sachs, an active investor in India, has acquired shares previously held by ChrysCapital and other existing shareholders.
The private equity arm of Goldman Sachs, is all set to acquire about 33% stake in Hyderabad-based GVK Biosciences, making pharma & healthcare as the favourite investment destination amid Covid pandemic, ET reported on Monday. ....

United States , Andhra Pradesh , Raghav Ramdev , Warburg Pincus , Sanjay Reddy , Manni Kantipudi , Biocon Biologics , Aragen Life Sciences , Contract Research Organization , Goldman Sachs Inc , Goldman Sachs , Aragen Bioscience Inc , Carlyle Group , Nova Medical Centers , Ranbaxy Laboratories , Singapore Temasek Holdings , Syngene International , Wall Street , General Atlantic , Quadria Capital , Biocon Backed Syngene , Aragen Bioscience , Aragen Life , Rajat Sood , Goldman Sachs Asset , Cytecare Hospitals ,

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
First Patient Dosed in Validive
®
Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021
Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery
WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2021 financial results and recent business updates.
Recent Business Updates
Validive
Monopar’s Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC) dosed its first patient in February 2021 and is actively recruiting ....

United States , Monopar Northstar , Kimr Tsuchimoto , Company Nasdaq , Aragen Bioscience Inc , Monopar Therapeutics Inc , Company Capital On , Exchange Commission , Trademark Office , Development Rd Expenses , Jonestrading Institutional Services , Texas Lung Injury Institute , Isotherapeutics Group , First Patient Dosed , Run In Clinical Trial Now Planned , Utility Reported , Imaging Agent , Monopar Therapeutics , Northstar Medical Radioisotopes , Aragen Bioscience , Texas Health Science Center , European Journal , Antibody Fragment , Urokinase Plasminogen Activator , Fast Delineation , Triple Negative Breast Cancer ,